Gut hormone coactivators, exemplified by GLP-1/GIP receptor co-agonists, are utilized in the clinical management of T2DM due to their efficacy in promoting weight loss and lowering lipid and blood glucose levels while exhibiting minimal side effects [154]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.